Monograph
M01CB03 - Auranofin |
Propably not porphyrinogenic |
PNP |
Rationale
Auranofin is most probably not an inhibitor or inducer of CYP enzymes.
Risk for gastrointestinal adverse events in the form of abdominal pain and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Auranofin is indicated for the treatment of rheumatoid arthritis.
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are abdominal pain and diarrhoea.
Metabolism and pharmacokinetics
About 25% of a given dose of auranofin is absorbed (Gottlieb 1986 and SPC). 40% of the absorbed dose is excreted in faeces and 60% is excreted in urine. Half-life elimination is 15-30 days with big individual differences.
No drug-drug interactions with auranofin as a perpetrator are observed (Interaksjoner and Interaktionsdatabasen), which may indicate that auranofin is not an inhibitor or inducer of CYP enzymes.
Published experience
Auranofin is listed to have been associated with acute attacks of porphyria (Moore 1997).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Pharmacology of auranofin: overview and update.
Gottlieb NL. Scand J Rheumatol Suppl. 1986;63:19-28. |
3110942 |
| 2. | Drugs in the acute porphyrias--toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):89-94.
Moore MR, Hift RJ. |
9074793 |
| * | Drug interaction databases | |
| 3. | Interaksjoner. Auranofin
|
|
| 4. | Interaktionsdatabasen. Auranofin
|
|
| * | Summary of Product Characteristics | |
| 5. | Swedish National Formulary. FASS. Summary of Product Characteristics (SPC). Auranofin. www.fass.se
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway© NAPOS 2024